It is made available under a CC-BY-NC-ND 4.0 International license .

Obesity in the Asia-Pacific body mass index classification is associated with the development of chronic kidney disease in non-diabetic Japanese men and women

# Authors' names and affiliations

Yukari Okawa<sup>1,2</sup>, Toshiharu Mitsuhashi<sup>3</sup>, and Toshihide Tsuda<sup>4</sup>

<sup>1</sup>Department of Public Health and Welfare, Zentsuji City Hall, 2-1-1 Bunkyo-cho, Zentsuji,

Kagawa 765-8503, Japan

<sup>2</sup>Clinical Research Institute, Ohara HealthCare Foundation, 1-1-1 Miwa, Kurashiki, Okayama

710-8602, Japan

<sup>3</sup>Center for Innovative Clinical Medicine, Okayama University Hospital, 2-5-1 Shikata-cho,

Kita-ku, Okayama 700-8558, Japan

<sup>4</sup>Department of Human Ecology, Graduate School of Environmental and Life Science, Okayama

University, 3-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan

# **Corresponding author**

Yukari Okawa

Department of Public Health and Welfare, Zentsuji City Hall, 2-1-1 Bunkyo-cho, Zentsuji,

Kagawa 765-8503, Japan

https://orcid.org/0000-0002-1704-6609

Tel. +81 877 63 6308

Fax. +81 877 63 6368

E-mail okw3923@gmail.com

It is made available under a CC-BY-NC-ND 4.0 International license .

# Abstract

Obesity is a risk factor for the development of chronic kidney disease (CKD). However, little is known about the relationship between the Asia-Pacific body mass index classification (Asia-Pacific classification) and the development of CKD in non-diabetic Asian adults.

CKD was defined as an estimated glomerular filtration rate <60 mL/min/1.73 m<sup>2</sup>. Body mass index (BMI) was categorized in accordance with the Asia-Pacific classification: underweight (<18.5 kg/m<sup>2</sup>), normal weight (18.5–22.9 kg/m<sup>2</sup>), overweight (23.0–24.9 kg/m<sup>2</sup>), obesity class I (25.0–29.9 kg/m<sup>2</sup>), and obesity class II ( $\geq$ 30.0 kg/m<sup>2</sup>). Using administrative checkup data for non-diabetic Japanese adults (1998–2023), we assessed the relationship between time-varying BMI in the Asia-Pacific classification and the development of CKD by sex. The generalized gamma model was selected because the proportional hazards assumption was violated.

In total, 34.2% of 3098 men and 34.8% of 4391 women had developed CKD. The mean follow-up time was 7.41 years for men and 8.25 years for women. Obesity classes I and II tended to have shorter survival time to CKD development for both sexes than normal weight. Fully-adjusted time ratios (95% confidence intervals) were 0.94 (0.90–0.98) and 0.92 (0.82–1.02) for men, and 0.95 (0.93–0.98) and 0.98 (0.92–1.05) for women, respectively.

Among non-diabetic Japanese adults, obesity class I in the Asia-Pacific classification was associated with a shorter survival time to CKD onset than normal weight. Low point estimates for obesity class II suggested a dose-response relationship in men but a less clear relationship in women. The conventional cutoff value for obesity, BMI  $\geq$  30.0 kg/m<sup>2</sup>, may be too high a risk factor for the development of CKD in non-diabetic Japanese men and women.

It is made available under a CC-BY-NC-ND 4.0 International license .

# Keywords

Body mass index, Chronic kidney disease, East Asian, Longitudinal studies, Risk factors

It is made available under a CC-BY-NC-ND 4.0 International license .

# Introduction

Diabetes is a major cause of chronic kidney disease (CKD) because the hyperglycemia caused by diabetes damages renal vessels over time<sup>1</sup>. Several studies that have examined the relationship between various exposures and incident CKD have treated glycemic control status (e.g., fasting blood sugar levels, prevalent diabetes) as a confounding factor that is adjusted to reduce bias<sup>2,3</sup>. However, even after adjusting for the glycemic control status, the effect of diabetes-induced bias may remain because diabetes increases the risk of various factors that cause selection bias (e.g., coronary heart disease, ischemic stroke, and death)<sup>4,5</sup>. Therefore, studies evaluating risk factors for the development of CKD in non-diabetic populations are important.

Obesity is a risk factor for developing CKD<sup>6</sup>. A previous meta-analysis in which the results of 13 cohort studies were combined reported that the risk of an individual with obesity developing CKD was 1.28 times greater than that of a person of normal weight; however, no clear association was observed in individuals with overweight. These studies used multiple definitions of obesity and CKD, included participants with and without diabetes from multiple ethnic groups, and did not show sex-specific results. Therefore, studies that include sex-stratified, mono-ethnic, and non-diabetic participants are needed to more accurately evaluate the relationship between obesity and the development of CKD.

A previous cohort study of non-diabetic Japanese adults examined whether a doseresponse relationship exists between body mass index (BMI) and the development of  $CKD^7$ . The study categorized BMI into seven groups and reported that individuals in the BMI categories  $\geq 23.0 \text{ kg/m}^2$  for men and  $\geq 27.0 \text{ kg/m}^2$  for women were at an elevated risk of developing CKD compared with the reference group. This suggests that even in a non-diabetic Asian population, elevated BMI is associated with the development of CKD and that sex differences are observed.

It is made available under a CC-BY-NC-ND 4.0 International license .

However, these results cannot simply be compared with previous findings because the studies use different BMI cutoff values and reference groups<sup>6,7</sup>. Therefore, sex-stratified studies in single-ethnic and non-diabetic populations that include a global standard BMI classification that accounts for racial differences are needed to examine the relationship between BMI and the development of CKD.

The World Health Organization Western Pacific Region proposed the Asia-Pacific BMI classification (Asia-Pacific classification)<sup>8</sup>. The classification has a lower BMI cutoff value than the conventional World Health Organization BMI classification (conventional BMI classification) that is used for all races because Asians have higher morbidity and mortality even with a lower BMI. Therefore, the Asia-Pacific classification should be used when assessing the relationship between BMI and CKD onset in Asian populations. On the basis of the above, the study's purpose was to investigate the relationship between BMI that was defined using the Asia-Pacific classification and the subsequent development of CKD in non-diabetic Japanese men and women.

#### Materials and methods

# **Data source**

The study was an ongoing open population-based longitudinal study of citizens of Zentsuji City, Kagawa Prefecture, Japan<sup>9</sup>. We used anonymized annual health checkup data from Zentsuji City from 6 April 1998 to 19 April 2023. On 1 April 2023, the city had a population of 30431 (men: 49.7%), with 38.1% of citizens aged  $\geq 60$  years<sup>9</sup>. The city database used in the previous studies was used for data extraction<sup>10,11</sup>. The data extraction date was 6 July 2023.

It is made available under a CC-BY-NC-ND 4.0 International license .

All citizens aged  $\geq$ 40 years were eligible to receive a health checkup once every fiscal year (FY). In FYs 1998 and 1999 only, younger citizens aged 34–39 years were added to the eligible population on a trial basis to promote the health of younger people. In past years, approximately 30%–40% of the eligible population had received a checkup.

In checkups, the participants underwent anthropometric measurements, a blood pressure test, a blood test, and a urine dipstick test, and answered a questionnaire about their lifestyle. The participants were not obliged to participate in a checkup, take all of the tests, or answer the questionnaire. Checkups were conducted in accordance with the protocol of the Ministry of Health, Labour and Welfare<sup>12</sup>.

### **Study participants**

This study aimed to evaluate the relationship between BMI and the development of CKD in nondiabetic Japanese men and women. Therefore, this study included all Japanese men and women aged  $\geq$ 34 years who underwent their first checkup between 1998 and 2023, who were free of diabetes and CKD at study entry, and who had follow-up data to confirm the onset of CKD. The participants who developed diabetes during the follow-up were regarded as right-censored. Diabetes was defined as HbA1c  $\geq$ 6.5%<sup>13</sup>. The following exclusion criteria were applied: non-Japanese, those with missing exposure and/or outcome data, prevalent CKD and/or diabetes at study entry, missing hemoglobin A1c (HbA1c) values, prevalent diabetes at study entry, and only one observation.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### Measures

#### Exposure

The exposure variable was obesity. BMI was used as the obesity definition. BMI was calculated by dividing weight (kg) by height (m) squared. Obesity was defined in accordance with the Asia-Pacific classification: underweight (<18.5 kg/m<sup>2</sup>), normal weight (18.5–22.9 kg/m<sup>2</sup>), overweight (23.0–24.9 kg/m<sup>2</sup>), obesity class I (25.0–29.9 kg/m<sup>2</sup>), and obesity class II ( $\geq$ 30.0 kg/m<sup>2</sup>)<sup>8</sup>. The BMI classification was time-varying in this analysis.

# Outcome

The outcome variable in this study was the development of CKD. The estimated glomerular filtration rate (eGFR) was used as a measure of renal function<sup>14</sup>. We used the three-variable revised Japanese equation to estimate glomerular filtration rate (GFR): eGFR (mL/min/1.73m<sup>2</sup>) =  $194 \times \text{serum creatinine (mg/dL)}^{-1.094} \times \text{age (years)}^{-0.287}$  (× 0.739, if female)<sup>15</sup>. Prevalent CKD was defined as eGFR <60 mL/min/1.73 m<sup>214</sup>. Serum creatinine (SCr) values in mg/dL were used up to two decimal places. The enzymatic method was used to measure SCr. Other information that is useful for determining the prevalence of CKD, such as a definitive diagnosis by a physician, was not available and could not be used in this analysis.

#### **Other covariates**

Sex was defined as a participant's physical characteristics at birth. Age (34–59[reference]/60– 69/70–100), self-reported alcohol intake (non- or seldom-drinker[reference]/drinker), selfreported smoking status (non- or ex-smoker[reference]/smoker), hypertension (no[reference]/yes), dyslipidemia (no[reference]/yes), HbA1c values (%), and residential district

It is made available under a CC-BY-NC-ND 4.0 International license .

(East[reference]/West/Central/South/Fudeoka/Tatsukawa/Yogita/Yoshiwara) were treated as covariates for adjustment<sup>6</sup>.

Hypertension was defined as systolic blood pressure  $\geq 130$  mm Hg and/or diastolic blood pressure  $\geq 80$  mm Hg<sup>16</sup>. Dyslipidemia was regarded as serum low-density lipoprotein cholesterol  $\geq 140$  mg/dL, serum high-density lipoprotein cholesterol <40 mg/dL, and/or serum triglycerides  $\geq 150$  mg/dL<sup>17</sup>. HbA1c was reported in Japan Diabetes Society units from 1998 to 2012 and in National Glycohemoglobin Standardization Program units from 2013 to 2023<sup>18</sup>. HbA1c levels were standardized to National Glycohemoglobin Standardization Program values using the officially certified equation: HbA1c<sub>NGSP</sub> (%) =  $1.02 \times \text{HbA1c}_{\text{JDS}}$  (%) +  $0.25^{19}$ . Neighborhood indicators (e.g., food quality and availability) have been reported to be related to obesity, diabetes, and possibly CKD<sup>20</sup>. Therefore, to reduce the potential impact of where participants resided within the city, the district of residence was treated as a covariate.

# **Statistical analysis**

All analyses were conducted separately for men and women. The participants' characteristics were summarized by BMI class. The person-years at risk were calculated from the date of the first participation to the date of onset of CKD or diabetes or the end of the last observation during the follow-up period. The participant demographics during the follow-up period were expressed as numbers by CKD onset, total person-years at risk, and incidence rate per 1000 person-years.

We created Kaplan–Meier curves by Asia-Pacific classification for men and women. We assessed the proportional hazards assumption using log–log plots and the Schoenfeld residuals<sup>21</sup>. We observed that the assumption was violated in this study. Therefore, the generalized gamma

It is made available under a CC-BY-NC-ND 4.0 International license .

model was selected for this analysis in accordance with the Akaike and Bayesian information criteria because the BMI classification was time-varying throughout the long follow-up from 1998 to 2023<sup>21–24</sup>. The time ratio and its 95% confidence interval (CI) were a measure of the effect of exposure on an outcome of interest. For example, a time ratio of 0.9 signified a 0.9-fold longer survival to CKD onset than the reference group.

Three adjusted models were constructed in addition to the crude model. Model 1 adjusted for age category; Model 2 further adjusted for self-reported alcohol intake and smoking status; Model 3 further adjusted for hypertension, dyslipidemia, and HbA1c values, and the residential district. To stabilize the models, a multiplicative term was added to Models 1–3 if an interaction effect between the exposure and the following variables was observed: age category, selfreported alcohol intake, self-reported smoking status, hypertension, dyslipidemia, and HbA1c values.

Given the nature of the voluntary checkup, missing values were observed for selfreported alcohol intake (missing in 34.0% of men and 32.7% of women), self-reported smoking status (missing in 31.1% of men and 30.4% of women), hypertension (not missing in men and missing in 0.02% of women), dyslipidemia (missing in 19.2% of men and 27.0% of women), and the residential district (1.33% of men and 1.42% of women). Missing measurements were complemented using multiple imputation methods with chained equations with 40 imputations<sup>25,26</sup>. Binary variables and categorical variables were imputed using logistic regression and multinominal logistic regression, respectively. Only imputed results were presented in this study because missing measurements were considered missing at random.

In this study, there was a large percentage of missing information on medication use of 59.4%. This large value was caused by a change in a questionnaire created by the Ministry of

It is made available under a CC-BY-NC-ND 4.0 International license .

Health, Labour and Welfare. A question asking about medication use was added in 2012 and removed in 2020 for older people aged  $\geq$ 75 years<sup>12</sup>. The use of information on medication use in the models was avoided because this age-related imbalance could induce bias.

We restricted the presentation to the results of the main exposure variable only to avoid the Table 2 fallacy<sup>27</sup>. A two-tailed p-value of less than 0.05 was treated as statistically significant. All statistical analyses were performed using Stata/MP 16.1 (StataCorp, College Station, TX, USA). A participant flow was drawn in Python 3.11.5<sup>28</sup>. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology reporting guidelines<sup>29</sup>.

# Sensitivity analyses

Three sensitivity analyses were conducted in this study. In the first sensitivity analysis, conventional BMI classification (underweight [<18.5 kg/m<sup>2</sup>], normal weight [18.5–24.9 kg/m<sup>2</sup>], overweight [25.0–29.9 kg/m<sup>2</sup>], obesity class I [30.0–34.9 kg/m<sup>2</sup>], obesity class II [35.0–39.9 kg/m<sup>2</sup>], and obesity class III [ $\geq$ 40.0 kg/m<sup>2</sup>]) were treated as exposure variables<sup>30</sup>. Obesity classes I–III were combined as one obesity category because of the small number of participants in this study with BMI  $\geq$ 30.0 kg/m<sup>2</sup>.

In the second sensitivity analysis, to minimize the possibility of reverse causation, we excluded the participants who developed CKD at the second observation. The third sensitivity analysis attempted to eliminate temporary abnormal eGFR values by including the stringent definition of CKD, in which CKD is defined by two or more consecutive observations of eGFR <60 mL/min/1.73 m<sup>2</sup>. Because the study included data from annual checkups, the duration of renal dysfunction in the stringent CKD definition was longer than that in the KDIGO definition of 3 months or longer<sup>14</sup>.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### Results

#### Main analysis

The initial participants were 6309 men and 9192 women, with a mean age at study entry of 70.0 years for men and 68.3 years for women. After exclusion, 3098 men (mean age at study entry: 59.0 years) and 4391 women (mean age at study entry: 62.1 years) who received checkups from 7 May 1998 to 19 April 2023 remained in the final cohort (**Figure 1**).

The Kaplan–Meier curves stratified by BMI category in men and women are provided in **Figure 2**. The participants' characteristics by Asia-Pacific BMI classification during follow-up are presented in **Table 1** for men and **Table 2** for women. The mean follow-up time was slightly longer in women (8.25 years) than in men (7.41 years). For both men and women, obesity class II ( $\geq$ 30.0 kg/m<sup>2</sup>) had the shortest follow-up time, accounting for <3% of the total follow-up time. Men with higher BMI were more likely to have hypertension and/or dyslipidemia, and women with higher BMI were more likely to have hypertension. After 25 years of follow-up, 34.2% of men and 34.8% of women developed CKD.

Our main analysis examined the relationship between the Asia-Pacific classification and later-onset CKD by sex (**Table 3**). Similar results were observed in men and women. Men and women in obesity class I had a 6% and 5% shorter survival time to CKD onset, respectively, than those of normal weight. Men in obesity class II had the shortest survival to CKD onset with a point estimate of 8%; however, the 95% CIs were across 1 in all of the models. For women in obesity class II, the results were almost null. Overweight was associated with higher point estimates (i.e., close to 1) compared with obesity categories, especially null values in women. A dose-response relationship by the point estimate was only observed in men. In particular, women

It is made available under a CC-BY-NC-ND 4.0 International license .

had a longer survival time to the development of CKD in the BMI category  $\ge 30.0 \text{ kg/m}^2$  than in the BMI category of 25.0–29.9 kg/m<sup>2</sup> by the point estimate.

#### Sensitivity analyses

In the first sensitivity analysis in which the conventional BMI classification was used, more participants (68.9% of men and 71.0% of women) were classified as having normal weight than in the main analysis in which the Asia-Pacific classification (43.3% of men and 50.6% of women) was used (**Tables 1–2, S1**). The results were similar for the obesity group using the conventional BMI classification and the obesity class II group using the Asia-Pacific classification (**Table 3**). Overweight was associated with a shorter survival than normal weight in each sex, similar to the results for obesity class I in the Asia-Pacific classification (**Table 3**).

The second sensitivity analysis attempted to minimize reverse causation by excluding the participants who had developed CKD at the second observation and included 2723 men and 3822 women. The mean age at study entry (61.4 years for men and 58.3 years for women) was higher for men and lower for women than in the main analysis. The mean follow-up period of the second sensitivity analysis was 8.14 years for men and 9.14 years for women—slightly longer than those in the main analysis (**Tables 1–2**). The distribution of follow-up time by BMI category was similar to that of the main analysis. After the follow-up period, 25.1% of men and 25.2% of women developed CKD—lower than in the main analysis. Most estimation results were similar to those of the main analysis; however, point estimates of survival for obesity class II were longer in men and shorter in women than those in the main analysis (**Table 3 and S2**).

**Table S3** shows the results of the third sensitivity analysis, which was based on thestringent definition of CKD and in which two consecutive observations of eGFR <60</td>

mL/min/1.73m<sup>2</sup> were regarded as CKD. Using the stringent definition of CKD, more participants (3380 men and 4963 women) remained in the final cohort, the mean follow-up time was longer (8.13 years for men and 9.29 years for women), and fewer participants developed CKD (20.7% of men and 21.1% of women) compared with the results of the main analysis (**Tables 1–2**). The mean age at study entry (62.6 years for men and 59.6 years for women) was higher for men and lower for women than in the main analysis. In men, point estimates for overweight, obesity class I, and obesity class II were similar to those in the main analysis, including the category with the shortest follow-up period, BMI  $\geq$  30.0 kg/m<sup>2</sup> (**Tables 3 and S3**). However, there were convergence errors in the results for women in Model 3.

# Discussion

# Main analysis

In the current analysis based on annual health checkups from 1998 to 2023 in non-diabetic Japanese adults, obesity class I as defined by the Asia-Pacific classification was associated with the earlier development of CKD. The 95% CIs for overweight and obesity class II were across 1 in all models; however, the point estimates implied a dose-response relationship, especially in men (**Table 3**). In all of the analyses, the results for the crude and adjusted models were similar, suggesting a lack of solid evidence that covariates affect the association between exposure and outcome.

These results partly agreed with those of the Ibaraki Prefecture Health Study (IPHS), a previous cohort study in diabetes-free Japanese participants<sup>7,31</sup>. The IPHS showed the dose-response relationship between BMI categories and the onset of CKD: aHRs were higher in BMI categories 23.0–24.9, 25.0–26.9, 27.0–29.9, and  $\geq$ 30.0 kg/m<sup>2</sup> in men and 27.0–29.9 and  $\geq$ 30.0

It is made available under a CC-BY-NC-ND 4.0 International license .

 $kg/m^2$  in women compared with the BMI category 21.0–22.9 kg/m<sup>2</sup>. In the current study, men but not women had a dose-response relationship by the point estimate.

Three factors may have influenced the difference between the results of these two studies<sup>7</sup>. First, the number of participants in our study (n = 7489) was smaller than that of the IPHS (n = 89760). Both studies included non-diabetic Japanese adults and reflected the Asian characteristic of low obesity prevalence (<3% of the total population)<sup>7,32,33</sup>. Therefore, the study's power may have been insufficient to detect a true effect in a small number of participants with BMI  $\geq$  30.0 kg/m<sup>2</sup>. Second, our participants were older than those in the IPHS. The age of our study participants ranged from 34 to 100 years compared with a range of 40 to 79 years in the IPHS. Consequently, efforts were made to mitigate bias by adjusting for age, thus reducing the likelihood of significant over- and underestimation from older adults' tendency toward a lower BMI<sup>34</sup>. Notably, however, the generalizability of this study's findings to populations of different ages is limited. Third, the observational period for our study was longer (1998–2023) than that of the IPHS (1993–2006). As the follow-up period increases, participants' susceptibility to outcomes decreases<sup>35</sup>. Specifically, our study had more built-in selection bias than the IPHS, which may have led to an underestimation of our results.

In this study, men had shorter survival by point estimate at a BMI  $\geq$  23.0 kg/m<sup>2</sup>, whereas women had shorter survival at a BMI  $\geq$  25.0 kg/m<sup>2</sup>. Therefore, men had a shorter survival time to CKD onset than women with the same BMI. This trend was consistent with that in the IPHS and previous findings and is partly explained by sex differences<sup>7,36</sup>. First, men's higher muscle mass compared with women can lead to systematic errors in eGFR in men when the higher muscle is misclassified as low eGFR<sup>37,38</sup>. Consequently, the results are likely to be overestimated in men. However, the overestimation may have been attenuated by the large number in our study of older

It is made available under a CC-BY-NC-ND 4.0 International license .

participants (i.e., those aged  $\geq$ 70 years), whose low BMI and muscle mass may have contributed to the underestimation (**Tables 1–2**)<sup>34</sup>.

Second, men had shorter follow-up times than women, potentially resulting in larger random errors and wider 95% CIs than women. According to the checkup data for the Japanese general population in FY 2020, the prevalence of CKD (eGFR <60 mL/min/1.73m<sup>2</sup>) for men and women was 3.97% and 2.57%, respectively<sup>39</sup>. The prevalence of CKD in this study was higher than in the Japanese general population, resulting in more participants being excluded from the analysis because they had CKD at study entry (**Figure 1**). Therefore, unmeasured factors, especially in the BMI  $\geq$  30.0 kg/m<sup>2</sup> classification, may have a greater impact on the results of this study.

# Sensitivity analyses

In the first sensitivity analysis, the conventional BMI classification was used as exposure (**Table S1**). Obesity had the lowest point estimates for men and an almost null value for women, with all 95% CIs crossing 1. Compared with the findings of the main analysis, overweight, which corresponds to obesity class I in the Asia-Pacific classification, was associated with shorter survival to CKD. Thus, the cutoff value of BMI  $\geq$  30.0 kg/m<sup>2</sup> for obesity may be too high a risk factor for CKD in a non-diabetic Japanese population.

The second sensitivity analysis was conducted to minimize the possibility of reverse causation by excluding the participants who had developed CKD at the second observation (**Table S2**). The results for all but the highest category showed a similar trend to that in the main analysis (**Table 3**), suggesting no clear evidence of reverse causation between the BMI categories of less than 30.0 kg/m<sup>2</sup> and CKD onset. However, these findings indicate a possible

It is made available under a CC-BY-NC-ND 4.0 International license .

weak inverse association between the BMI  $\geq$  30.0 kg/m<sup>2</sup> category and CKD onset that may be partly due to the shorter follow-up period in the BMI  $\geq$  30.0 kg/m<sup>2</sup> category compared with those in the other categories (**Table S2**). As a result, the relationship between BMI  $\geq$  30.0 kg/m<sup>2</sup> and the development of CKD could not be fully assessed in all of the models because of reduced power—especially in men, who had the shortest survival to CKD onset by point estimate in the main analysis. Therefore, a type II error may exist in the BMI  $\geq$  30.0 kg/m<sup>2</sup> category, and a doseresponse relationship may exist between BMI and the development of CKD in this analysis.

The third sensitivity analysis, which was based on the stringent CKD definition and in which two consecutive observations of eGFR <60 mL/min/ $1.73m^2$  were considered CKD, showed a similar trend to that of the main analysis in Models 1–2 (**Tables 3 and S3**). Compared to the main analysis (1059 men and 1526 women), fewer participants developed CKD (700 men and 1049 women), causing convergence error in Model 3. The results of the third sensitivity analysis were similar to the results of the main analysis in Crude and Models 1–2, suggesting a certain robust relationship between BMI and incident CKD.

# **Strengths and limitations**

A strength of this study was that it used the Asia-Pacific BMI classification to evaluate the impact of elevated BMI on the development of CKD in non-diabetic monoracial Asian men and women using longitudinal data with a long follow-up period of approximately 25 years.

However, several limitations must be specified. First, because East Asians tend to have a lower BMI than Westerners, the number of participants with the highest category of BMI ( $\geq$ 30.0 kg/m<sup>2</sup>) was low in this study, and the relationship between BMI and subsequent development of CKD could not be fully assessed<sup>32</sup>. Second, high BMI is not equivalent to obesity. BMI is simply

It is made available under a CC-BY-NC-ND 4.0 International license .

a measure that is calculated based on weight and height and not body composition such as body fat percentage. When obesity is defined as body fat percentages of  $\geq 25\%$  for men and  $\geq 35\%$  for women in an Asian population, detecting obesity using a BMI  $\geq 30.0$  kg/m<sup>2</sup> has high specificity (97.3% for men and 95.0% for women) but low sensitivity (6.7% for men and 13.4% for women)<sup>40</sup>. Therefore, a BMI cutoff of  $\geq 30.0$  kg/m<sup>2</sup> misses most participants with high body fat and results in a misclassification that underestimates the highest BMI category.

Third, the exact date of CKD onset could not be known—a major and unresolved shortcoming of cohort studies that are based on annual checkup data and in which participants can decide when to be screened. These factors lead to interval censoring, which requires extremely complex statistical models to address<sup>41</sup>. Fourth, measurement errors in renal function may have occurred. Inulin clearance values, the gold standard for measuring GFR, could not be obtained in our study because the test is too time-consuming and expensive for inclusion in regular checkups by local governments<sup>36</sup>. Instead, we used SCr to estimate GFR using the three-variable revised Japanese equation, which is more accurate than the Modification of Diet in Renal Disease equations<sup>15</sup>.

Fifth, our study participants were healthier than the general population. A previous study reported that those who voluntarily attended checkups were more likely to be health-conscious and healthier than the general population<sup>42</sup>. This selection bias may be responsible for the underestimated results. Sixth, the presence of competing risks that may have modified the occurrence of an event such as death or hospitalization could not be assessed because the necessary data were unavailable.

Finally, indicators of central and visceral fat, such as waist circumference or waist-to-hip ratio, were not available. In the Hallym Aging Study, a cohort study of 454 adult Korean

It is made available under a CC-BY-NC-ND 4.0 International license .

participants, elevations in these factors were more strongly associated with CKD than BMI regardless of prevalent diabetes<sup>43</sup>. In addition, another review reported that the waist to height ratio is a better indicator of obesity and is associated with CKD<sup>44</sup>. In the future, these variables should be used together with BMI to create an obesity index that more clearly indicates the risk of developing CKD by race for men and women without diabetes.

# Conclusion

Our study of 7489 non-diabetic Japanese adults in which the Asia-Pacific BMI classification was used showed that men and women with obesity class I had 6% shorter survival to subsequent CKD than those of normal weight. Obesity class II had the shortest survival to CKD onset by point estimates in men and an almost null value in women, with all 95% CIs across 1. The results support previous findings of a dose-response relationship between BMI and the development of CKD, especially in men. Our results add new evidence to support that the BMI cutoff values for obesity that are based on the conventional BMI classification are too high when considering the association between obesity and future CKD development in non-diabetic Japanese men and women.

# Ethics

All data were anonymized before receipt. The Ethics Committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital approved this study (No. K1708-040). The Ethics Committee waived the need for informed consent. Study procedures were performed in accordance with the Declaration of

It is made available under a CC-BY-NC-ND 4.0 International license .

Helsinki and Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects.

# Acknowledgments

We are grateful to all participants of this study, Ayaka Nakatsu, Masako Matsumoto, Mayumi

Kitadani, and all local government officers of Zentsuji City for their support and contribution.

We thank Anahid Pinchis, BSc, MBA, and Ellen Knapp, PhD, from Edanz

(https://jp.edanz.com/ac) for editing a draft of this manuscript.

# **Competing interests**

This research received no specific grant from funding agencies in the public, commercial, or notfor-profit sectors. Y.O. is employed by Zentsuji City. T.M. and T.T. declare no potential competing interests.

# **Data statement**

All data generated or analyzed during this study are included in this published article and its supplementary information files.

It is made available under a CC-BY-NC-ND 4.0 International license .

# References

- 1. Shen Y, Cai R, Sun J, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: A systematic review and meta-analysis. *Endocrine*. 2017;55(1):66-76. doi:10.1007/s12020-016-1014-6
- Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. *CJASN*. 2011;6(10):2364-2373. doi:10.2215/CJN.02180311
- Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. *Dig Dis Sci*. 2015;60(12):3801-3813. doi:10.1007/s10620-015-3801-y
- 4. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *The Lancet*. 2010;375(9733):2215-2222. doi:10.1016/S0140-6736(10)60484-9
- 5. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting Glucose, and risk of cause-specific death. *N Engl J Med*. 2011;364(9):829-841. doi:10.1056/NEJMoa1008862
- 6. Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. *Kidney International*. 2017;91(5):1224-1235. doi:10.1016/j.kint.2016.12.013
- Tsujimoto T, Sairenchi T, Iso H, et al. The dose-response relationship between body mass index and the risk of incident stage ≥3 chronic kidney disease in a general Japanese population: The Ibaraki Prefectural Health Study (IPHS). *Journal of Epidemiology*. 2014;24(6):444-451. doi:10.2188/jea.JE20140028
- 8. World Health Organization Regional Office for the Western Pacific Region. *The Asia-Pacific Perspective: Redefining Obesity and Its Treatment*. Sydney: Health Communications Australia; 2000. Accessed September 21, 2024. https://iris.who.int/handle/10665/206936
- 9. Zentsuji City. Zentsuji City official website. Accessed October 31, 2024. https://www.city.zentsuji.kagawa.jp
- 10. Okawa Y, Suzuki E, Mitsuhashi T, Tsuda T, Yorifuji T. A population-based longitudinal study on glycated hemoglobin levels and new-onset chronic kidney disease among non-diabetic Japanese adults. *Sci Rep.* 2023;13(1):13770. doi:10.1038/s41598-023-40300-8
- Okawa Y, Mitsuhashi T. Association between blood pressure and new onset of chronic kidney disease in non-diabetic Japanese adults: a population-based longitudinal study from 1998 to 2023. *Nutrition, Metabolism and Cardiovascular Diseases*. Published online May 2024:S093947532400173X. doi:10.1016/j.numecd.2024.05.005

It is made available under a CC-BY-NC-ND 4.0 International license .

- Ministry of Health, Labour and Welfare. Specific health examination and specific health guidance. Accessed October 28, 2024. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000161103.html
- 13. ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and diagnosis of diabetes: *standards of care in diabetes—2023. Diabetes Care*. 2023;46(Supplement\_1):S19-S40. doi:10.2337/dc23-S002
- Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney International*. 2024;105(4):S117-S314. doi:10.1016/j.kint.2023.10.018
- 15. Matsuo S, Yasuda Y, Imai E, Horio M. Current status of estimated glomerular filtration rate (eGFR) equations for Asians and an approach to create a common eGFR equation: approach to eGFR equation for Asians. *Nephrology*. 2010;15:45-48. doi:10.1111/j.1440-1797.2010.01313.x
- 16. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. *Hypertension*. 2018;71(6):1269-1324. doi:10.1161/HYP.00000000000066
- Kinoshita M, Yokote K, Arai H, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. *J Atheroscler Thromb*. 2018;25(9):846-984. doi:10.5551/jat.GL2017
- 18. NGSP. NGSP Home. Accessed October 31, 2024. https://ngsp.org
- Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. *Journal of Diabetes Investigation*. 2012;3(1):39-40. doi:10.1111/j.2040-1124.2012.00207.x
- Lapedis CJ, Mariani LH, Jang BJ, Hodgin J, Hicken MT. Understanding the link between neighborhoods and kidney disease. *Kidney360*. 2020;1(8):845-854. doi:10.34067/KID.0001202019
- 21. Schoenfeld D. Partial residuals for the proportional hazards regression model. *Biometrika*. 1982;69(1):239-241. doi:10.1093/biomet/69.1.239
- 22. Akaike H. A new look at the statistical model identification. *IEEE Trans Automat Contr.* 1974;19(6):716-723. doi:10.1109/TAC.1974.1100705
- 23. Schwarz G. Estimating the dimension of a model. *Ann Statist*. 1978;6(2). doi:10.1214/aos/1176344136

- Cox C, Chu H, Schneider MF, Muñoz A. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. *Statistics in Medicine*. 2007;26(23):4352-4374. doi:10.1002/sim.2836
- 25. von Hippel PT. How many imputations do you need? A two-stage calculation using a quadratic rule. *Sociological Methods & Research*. 2020;49(3):699-718. doi:10.1177/0049124117747303
- 26. Young R, Johnson DR. Handling missing values in longitudinal panel data with multiple imputation. *Fam Relat.* 2015;77(1):277-294. doi:10.1111/jomf.12144
- 27. Westreich D, Greenland S. The Table 2 fallacy: presenting and interpreting confounder and modifier coefficients. *American Journal of Epidemiology*. 2013;177(4):292-298. doi:10.1093/aje/kws412
- 28. Python Software Foundation. Python. Python.org. April 5, 2023. Accessed October 28, 2024. https://www.python.org/
- 29. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. *Epidemiology*. 2007;18(6):805-835. doi:10.1097/EDE.0b013e3181577511
- World Health Organization. A healthy lifestyle WHO recommendations. Accessed October 31, 2024. https://www.who.int/europe/news-room/fact-sheets/item/a-healthy-lifestyle---whorecommendations
- 31. Ibaraki Prefectural Health Plaza. Ibaraki Prefectural Health Study: IPHS. Accessed October 31, 2024. https://www.hsc-i.jp/05\_chousa/iphs.htm
- 32. Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *The Lancet*. 2017;390(10113):2627-2642. doi:10.1016/S0140-6736(17)32129-3
- 33. The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med.* 2017;377(1):13-27. doi:10.1056/NEJMoa1614362
- 34. Tarui I, Okada E, Okada C, Saito A, Takimoto H. Trends in BMI among elderly Japanese population: findings from 1973 to 2016 Japan National Health and Nutrition Survey. *Public Health Nutr.* 2020;23(11):1907-1915. doi:10.1017/S1368980019004828
- 35. Hernán MA. The hazards of hazard ratios. *Epidemiology*. 2010;21(1):13-15. doi:10.1097/EDE.0b013e3181c1ea43
- Kidney Disease: Improving Global Outcomes (KDIGO). Chapter 1: definition and classification of CKD. *Kidney International Supplements*. 2013;3(1):19-62. doi:10.1038/kisup.2012.64

- 37. Janssen I, Heymsfield SB, Wang Z, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. *Journal of Applied Physiology*. 2000;89(1):81-88. doi:10.1152/jappl.2000.89.1.81
- 38. Nankivell BJ, Nankivell LFJ, Elder GJ, Gruenewald SM. How unmeasured muscle mass affects estimated GFR and diagnostic inaccuracy. *EClinicalMedicine*. 2020;29-30:100662. doi:10.1016/j.eclinm.2020.100662
- 39. Ministry of Health, Labour and Welfare. NDB Open Data. NDB Open Data. Accessed October 31, 2024. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177182.html
- 40. Goh VHH, Tain CF, Tong TYY, Mok HPP, Wong MT. Are BMI and other anthropometric measures appropriate as indices for obesity? A study in an Asian population. *Journal of Lipid Research*. 2004;45(10):1892-1898. doi:10.1194/jlr.M400159-JLR200
- 41. Chen L, Qiu B. Analysis of length-biased and partly interval-censored survival data with mismeasured covariates. *Biometrics*. Published online July 17, 2023:biom.13898. doi:10.1111/biom.13898
- 42. Bjerregaard AL, Maindal HT, Bruun NH, Sandbæk A. Patterns of attendance to health checks in a municipality setting: the Danish 'Check Your Health Preventive Program.' *Preventive Medicine Reports*. 2017;5:175-182. doi:10.1016/j.pmedr.2016.12.011
- 43. Oh H, Quan SA, Jeong JY, Jang SN, Lee JE, Kim DH. Waist circumference, not body mass index, is associated with renal function decline in Korean population: Hallym Aging Study. Vliegenthart R, ed. *PLoS ONE*. 2013;8(3):e59071. doi:10.1371/journal.pone.0059071
- 44. Liu L, Wang Y, Zhang W, Chang W, Jin Y, Yao Y. Waist height ratio predicts chronic kidney disease: a systematic review and meta-analysis, 1998–2019. *Arch Public Health*. 2019;77(1):55. doi:10.1186/s13690-019-0379-4

**Figure legends** 

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. Participant flow chart of the study cohort.





It is made available under a CC-BY-NC-ND 4.0 International license

|                           | Asia-Pacific BMI classification                     |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         |                      |  |
|---------------------------|---|--------|---------------|---------|--------|---|---------|--------|------|-----------------|--------|------|-------------------------------|--------|-------|---------|---------|----------------------|--|
|                           | $< 18.5 \text{ kg/m}^2$ 18.5–22.9 kg/m <sup>2</sup> |        |               |         |        | 23.0–24.9 kg/m <sup>2</sup> 25.0–29.9 kg/m <sup>2</sup> |         |        |      |                 |        |      | $\geq$ 30.0 kg/m <sup>2</sup> |        |       |         | Total   |                      |  |
|                           | Underweight   |        | Normal weight |         |        | Overweight  |         |        |      | Obesity class I |        |      | Obesity class II              |        |       |         |         |                      |  |
|                           | Failure   | PY     | IR*           | Failure | PY     | IR*   | Failure | PY     | IR*  | Failure         | PY     | IR*  | Failure                       | PY     | IR*   | Failure | PY      | IR*                  |  |
| Time at risk              |   |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         |                      |  |
| Total                     |   | 1145.5 |               |         | 9941.5 |   |         | 5877.1 |      |                 | 5532.7 |      |                               | 468.8  |       |         | 22965.6 |                      |  |
| Minimum                   |   | 0.71   |               |         | 0.40   |   |         | 0.46   |      |                 | 0.34   |      |                               | 0.60   |       |         | 0.34    |                      |  |
| Maximum                   |   | 20.4   |               |         | 24.5   |   |         | 23.2   |      |                 | 24.3   |      |                               | 22.2   |       |         | 24.5    |                      |  |
| Mean                      |   | 4.44   |               |         | 6.05   |   |         | 4.82   |      |                 | 5.23   |      |                               | 4.15   |       |         | 7.41    |                      |  |
| Median                    |   | 2.91   |               |         | 4.19   |   |         | 3.16   |      |                 | 3.89   |      |                               | 2.99   |       |         | 5.99    |                      |  |
| Failure/IR*               | 40  |        | 34.9          | 438     |        | 44.1  | 272     |        | 46.3 | 287             |        | 51.9 | 22                            |        | 46.9  | 1059    |         | 46.1                 |  |
| Variables                 |   |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         |                      |  |
| Age category in           | years   |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         |                      |  |
| 34–59                     | 2   | 241.9  | 8.3           | 35      | 2327.5 | 15.0  | 25      | 1671.4 | 15.0 | 39              | 1838.7 | 21.2 | 4                             | 223.8  | 17.9  | 105     | 6303.3  | 16. <u>7</u>         |  |
| 60–69                     | 11  | 353.9  | 31.1          | 168     | 3763.0 | 44.6  | 107     | 2140.8 | 50.0 | 114             | 1994.6 | 57.2 | 11                            | 137.3  | 80.1  | 411     | 8389.5  | 49. <del>J</del>     |  |
| 70-100                    | 27  | 549.7  | 49.1          | 235     | 3851.0 | 61.0  | 140     | 2064.9 | 67.8 | 134             | 1699.5 | 78.8 | 7                             | 107.7  | 65.0  | 543     | 8272.8  | 65. <b>Ð</b>         |  |
| Self-reported alc         | cohol intake  |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         | ade                  |  |
| Nondrinker                | 19.9  | 546.2  | 36.4          | 170.7   | 3732.4 | 45.7  | 114.1   | 2127.5 | 53.6 | 108.4           | 1972.1 | 55.0 | 8.5                           | 209.4  | 40.6  | 421.6   | 8587.6  | 49. <b>ğ</b>         |  |
| Drinker                   | 20.2  | 599.3  | 33.6          | 267.3   | 6209.2 | 43.0  | 157.9   | 3749.6 | 42.1 | 178.6           | 3560.7 | 50.2 | 13.5                          | 259.3  | 52.1  | 637.4   | 14378.0 | 44. <u>9</u> .       |  |
| Self-reported sm          | noker status  |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         | abl                  |  |
| Nonsmoker                 | 25.1  | 706.5  | 35.6          | 299.2   | 6659.9 | 44.9  | 205.4   | 4200.7 | 48.9 | 225.5           | 3916.6 | 57.6 | 18.6                          | 340.3  | 54.6  | 773.8   | 15823.9 | 48. <b>9</b>         |  |
| Smoker                    | 14.9  | 439.1  | 34.0          | 138.8   | 3281.7 | 42.3  | 66.6    | 1676.3 | 39.7 | 61.6            | 1616.2 | 38.1 | 3.4                           | 128.5  | 26.7  | 285.3   | 7141.7  | 39. <u>a</u>         |  |
| Hypertension <sup>†</sup> |   |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         | er                   |  |
| No                        | 22.0  | 647.0  | 34.0          | 190.0   | 5100.0 | 37.3  | 103.0   | 2426.9 | 42.4 | 85.0            | 1759.7 | 48.3 | 3.0                           | 128.5  | 23.3  | 403.0   | 10062.0 | 40. <mark>ക</mark> ് |  |
| Yes                       | 18.0  | 498.5  | 36.1          | 248.0   | 4841.6 | 51.2  | 169.0   | 3450.2 | 49.0 | 202.0           | 3773.0 | 53.5 | 19.0                          | 340.3  | 55.8  | 656.0   | 12903.6 | 50. <mark>8</mark>   |  |
| Dyslipidemia‡             |   |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         | Ϋ́                   |  |
| No                        | 24.0  | 693.4  | 34.6          | 196.4   | 4983.6 | 39.4  | 99.5    | 2316.5 | 42.9 | 93.8            | 1797.3 | 52.2 | 5.8                           | 128.5  | 44.8  | 419.4   | 9919.4  | 42. <mark>ਤ</mark>   |  |
| Yes                       | 16.0  | 452.1  | 35.5          | 241.6   | 4957.9 | 48.7  | 172.5   | 3560.5 | 48.5 | 193.2           | 3735.4 | 51.7 | 16.3                          | 340.2  | 47.8  | 639.6   | 13046.2 | 49. <mark>9</mark>   |  |
| Residential distr         | rict  |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         | Ū                    |  |
| East                      | 8.1   | 208.2  | 39.0          | 103.9   | 1986.6 | 52.3  | 53.0    | 1329.6 | 39.9 | 55.0            | 1071.1 | 51.4 | 3.2                           | 63.1   | 50.1  | 223.2   | 4658.7  | 47.8                 |  |
| Tatsukawa                 | 4.2   | 142.7  | 29.1          | 60.5    | 1755.3 | 34.4  | 40.0    | 976.3  | 41.0 | 44.1            | 893.3  | 49.4 | 3.2                           | 107.3  | 30.0  | 152.0   | 3874.9  | 39. <mark>⊒</mark>   |  |
| Central                   | 7.2   | 162.4  | 44.0          | 64.0    | 1246.0 | 51.4  | 30.0    | 677.8  | 44.3 | 34.7            | 666.1  | 52.0 | 1.2                           | 78.2   | 14.6  | 137.0   | 2830.4  | 48.4                 |  |
| Fudeoka                   | 2.1   | 116.7  | 18.2          | 38.9    | 1180.6 | 33.0  | 29.0    | 702.3  | 41.3 | 42.9            | 769.5  | 55.8 | 9.2                           | 90.4   | 101.5 | 122.2   | 2859.5  | 42.7                 |  |
| South                     | 5.2   | 176.5  | 29.2          | 49.1    | 1120.7 | 43.8  | 43.0    | 770.6  | 55.8 | 30.5            | 622.7  | 49.0 | 3.1                           | 63.8   | 48.5  | 130.9   | 2754.3  | 47. <mark>S</mark>   |  |
| West                      | 5.0   | 160.2  | 31.2          | 53.6    | 999.4  | 53.6  | 36.0    | 542.7  | 66.3 | 34.6            | 646.0  | 53.5 | 0.0                           | 17.4   | 1.0   | 129.2   | 2365.7  | 54. <mark>5</mark>   |  |
| Yoshiwara                 | 5.2   | 94.8   | 54.3          | 43.7    | 1050.5 | 41.6  | 28.0    | 608.8  | 46.0 | 28.7            | 456.2  | 63.0 | 1.1                           | 25.5   | 41.7  | 106.7   | 2235.9  | 47. <mark>a</mark>   |  |
| Yogita                    | 3.2   | 84.0   | 37.5          | 24.4    | 602.5  | 40.4  | 13.0    | 268.9  | 48.3 | 16.5            | 407.7  | 40.3 | 1.1                           | 23.1   | 46.0  | 58.0    | 1386.3  | 41.8                 |  |
| HbA1c values, 9           | %   |        |               |         |        |   |         |        |      |                 |        |      |                               |        |       |         |         | · ·                  |  |
| Mean (SD)                 | 5.39  | (0.37) |               | 5.40    | (0.40) |   | 5.43    | (0.42) |      | 5.49            | (0.42) |      | 5.59                          | (0.40) |       | 5.43    | (0.41)  |                      |  |

| Table 1. Descriptive statistics of all observations stratified | y the Asia-Pacific BMI classification in non-diabetic Jap | panese male citizens of Zentsuji City (1998-2023 |
|--|---|--|
|--|---|--|

Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1C; IR, incidence rate; SD, standard deviation.

Results for multiple imputed variables (self-reported alcohol intake, self-reported smoking status, hypertension<sup>†</sup>, dyslipidemia<sup>‡</sup>, and residential district) are averaged over 40 imputations. \*Incidence rate is reported per 1000 person-years.

†Hypertension is defined as systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg.

 $\pm$ Dyslipidemia is defined as serum low density lipoprotein cholesterol  $\geq$ 140 mg/dL, serum high density lipoprotein cholesterol <40 mg/dL, and/or serum triglycerides  $\geq$ 150 mg/dL.

|                              | Asia-Pacific BMI classification |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         |   |
|------------------------------|---------------------------------|---------|----------|---------|--|---------|---------|--------|-----------------|----------------------------|--------|------------------|-------------------------------|--------|------|---------|---------|---|
|                              | $< 18.5 \text{ kg/m}^2$ 18.5–2  |         |          |         | $.8.5-22.9 \text{ kg/m}^2$ 23.0-24.9 kg/m <sup>2</sup> |         |         |        |                 | $25.0-29.9 \text{ kg/m}^2$ |        |                  | $\geq$ 30.0 kg/m <sup>2</sup> |        |      | Total   |         | ole   |
|                              | Underweight                     |         | Normal v | veight  |  | Overwei | ght     |        | Obesity class I |                            |        | Obesity class II |                               |        |      |         | , pi    |   |
|                              | Failure                         | PY      | IR*      | Failure | PY   | IR*     | Failure | PY     | IR*             | Failure                    | PY     | IR*              | Failure                       | PY     | IR*  | Failure | PY      | IR* ₹   |
| Time at risk                 |                                 |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         |   |
| Total                        |                                 | 2804.2  |          |         | 18306.5  |         |         | 7424.3 |                 |                            | 6627.6 |                  |                               | 1055.4 |      |         | 36218.0 | CDV   |
| Minimum                      |                                 | 0.63    |          |         | 0.48   |         |         | 0.48   |                 |                            | 0.53   |                  |                               | 0.80   |      |         | 0.48    | Va  |
| Maximum                      |                                 | 24.3    |          |         | 24.7   |         |         | 22.8   |                 |                            | 24.3   |                  |                               | 20.3   |      |         | 24.7    | , in the second s |
| Mean                         |                                 | 4.95    |          |         | 7.00   |         |         | 5.09   |                 |                            | 5.49   |                  |                               | 4.91   |      |         | 8.25    | 2   |
| Median                       |                                 | 3.05    |          |         | 5.05   |         |         | 3.63   |                 |                            | 3.87   |                  |                               | 3.10   |      |         | 6.83    | ĕ   |
| Failure/IR*                  | 106                             |         | 37.8     | 697     |  | 38.1    | 307     |        | 41.4            | 371                        |        | 56.0             | 45                            |        | 42.6 | 1526    |         | 42.1  |
| Variables                    |                                 |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         | ä   |
| Age category in years        |                                 |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         | _ 9   |
| 34–59                        | 23                              | 1137.7  | 20.2     | 187     | 7825.2   | 23.9    | 70      | 2392.4 | 29.3            | 73                         | 1980.3 | 36.9             | 9                             | 436.8  | 20.6 | 362.0   | 13772.4 | 26.3  |
| 60–69                        | 23                              | 761.2   | 30.2     | 199     | 5690.4   | 35.0    | 93      | 2816.1 | 33.0            | 117                        | 2455.0 | 47.7             | 12                            | 300.7  | 39.9 | 444.0   | 12023.4 | 36.9 9  |
| 70–100                       | 60                              | 905.2   | 66.3     | 311     | 4790.9   | 64.9    | 144     | 2215.9 | 65.0            | 181                        | 2192.3 | 82.6             | 24                            | 317.9  | 75.5 | 720.0   | 10422.2 | 69.9  |
| Self-reported alcohol intake |                                 |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         | e<br>aj e   |
| Nondrinker                   | 86.2                            | 2085.0  | 41.3     | 532.3   | 13267.3  | 40.1    | 238.1   | 5518.0 | 43.1            | 303.4                      | 5153.4 | 58.9             | 39.4                          | 819.4  | 48.0 | 1199.3  | 26843.1 | 44.9 3  |
| Drinker                      | 19.9                            | 719.1   | 27.6     | 164.7   | 5039.3   | 32.7    | 68.9    | 1906.4 | 36.2            | 67.6                       | 1474.2 | 45.8             | 5.7                           | 236.0  | 23.9 | 326.7   | 9375.0  | 34.80 =   |
| Self-reported smoker status  |                                 |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         | le u  |
| Nonsmoker                    | 102.6                           | 2568.8  | 39.9     | 668.3   | 17266.9  | 38.7    | 297.0   | 7090.5 | 41.9            | 362.5                      | 6334.9 | 57.2             | 43.8                          | 991.1  | 44.2 | 1474.3  | 34252.2 | 43. Đ   |
| Smoker                       | 3.4                             | 235.4   | 14.5     | 28.7    | 1039.7   | 27.6    | 10.0    | 333.8  | 30.0            | 8.5                        | 292.8  | 29.1             | 1.2                           | 64.3   | 18.4 | 51.8    | 1965.9  | 26.3 2  |
| Hypertension*                |                                 |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         | a   |
| No                           | 53.0                            | 1950.8  | 27.2     | 330.0   | 10753.6  | 30.7    | 110.0   | 3377.2 | 32.6            | 113.0                      | 2314.1 | 48.8             | 11.0                          | 243.3  | 45.2 | 617.0   | 18639.0 | 33. <b>Ý</b> Z  |
| Yes                          | 53.0                            | 853.3   | 62.1     | 367.0   | 7553.0   | 48.6    | 197.0   | 4047.2 | 48.7            | 258.0                      | 4313.5 | 59.8             | 34.0                          | 812.0  | 41.9 | 909.0   | 17579.0 | 51.7  |
| Dyslipidemia <sup>†</sup>    |                                 |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         | ż s   |
| No                           | 64.6                            | 1776.0  | 36.4     | 330.1   | 9347.6   | 35.3    | 119.3   | 3067.8 | 38.9            | 126.4                      | 2521.8 | 50.1             | 16.5                          | 404.0  | 40.8 | 656.9   | 17117.1 | 38.4 =  |
| Yes                          | 41.5                            | 1028.1  | 40.4     | 366.9   | 8959.0   | 41.0    | 187.7   | 4356.6 | 43.1            | 244.6                      | 4105.8 | 59.6             | 28.5                          | 651.4  | 43.8 | 869.1   | 19100.9 | 45.5  |
| Residential district         |                                 |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         | 9r  |
| East                         | 22.0                            | 508.0   | 43.3     | 132.8   | 3621.6   | 36.7    | 57.8    | 1429.9 | 40.4            | 76.7                       | 1447.1 | 53.0             | 8.0                           | 215.2  | 37.2 | 297.3   | 7221.8  | 41.3  |
| Tatsukawa                    | 15.0                            | 557.7   | 26.9     | 101.0   | 3329.9   | 30.3    | 57.0    | 1223.3 | 46.6            | 52.6                       | 1102.7 | 47.7             | 7.0                           | 170.3  | 41.1 | 232.6   | 6383.9  | 36. <mark>3</mark> 🗳  |
| Central                      | 21.0                            | 452.7   | 46.4     | 106.5   | 2508.4   | 42.5    | 43.0    | 950.6  | 45.2            | 51.3                       | 874.0  | 58.7             | 11.0                          | 157.2  | 70.0 | 232.8   | 4943.0  | 47.   |
| Fudeoka                      | 10.0                            | 278.3   | 35.9     | 93.4    | 2344.1   | 39.8    | 31.8    | 954.4  | 33.3            | 49.5                       | 858.1  | 57.7             | 3.0                           | 146.8  | 20.4 | 187.7   | 4581.7  | 41.   |
| South                        | 11.0                            | 363.7   | 30.3     | 70.1    | 1917.1   | 36.6    | 31.8    | 808.7  | 39.3            | 39.5                       | 702.6  | 56.3             | 4.0                           | 109.7  | 36.5 | 156.4   | 3901.8  | 40.1 ¥  |
| West                         | 6.0                             | 292.9   | 20.5     | 69.0    | 1903.6   | 36.3    | 38.7    | 791.4  | 48.8            | 43.4                       | 586.3  | 74.1             | 5.0                           | 111.0  | 45.1 | 162.1   | 3685.2  | 44. <b>8</b> 🗳  |
| Yoshiwara                    | 10.0                            | 192.0   | 52.1     | 80.8    | 1773.7   | 45.5    | 28.6    | 819.1  | 34.9            | 35.6                       | 591.0  | 60.2             | 4.0                           | 96.0   | 41.7 | 159.0   | 3471.8  | 45.8  |
| Yogita                       | 11.0                            | 158.7   | 69.3     | 43.5    | 908.1  | 47.8    | 18.4    | 447.0  | 41.1            | 22.4                       | 465.8  | 48.0             | 3.0                           | 49.3   | 61.0 | 98.2    | 2029.0  | 48.4  |
| HbA1c values, %              |                                 |         |          |         |  |         |         |        |                 |                            |        |                  |                               |        |      |         |         | e   |
| Mean (SD)                    | 5.45                            | (0.34)  |          | 5.45    | (0.38)   |         | 5.50    | (0.39) |                 | 5.53                       | (0.39) |                  | 5.54                          | (0.37) |      | 5.48    | (0.38)  | G<br>G  |
|                              |                                 | (2.2.1) |          |         | (0.00)   |         |         | (0.02) |                 | 2.20                       | (0.07) |                  |                               | (      |      | 20      | (0.00)  | <u>s</u>  |

Table 2. Descriptive statistics of all observations stratified by the Asia-Pacific BMI classification among 4391 non-diabetic Japanese female citizens of Zentsuji City (1998–2023)

Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1C; IR, incidence rate; SD, standard deviation.

Results for multiple imputed variables (self-reported alcohol intake, self-reported smoking status, hypertension\*, dyslipidemia<sup>+</sup>, and residential district) are averaged over 40 imputations. \*Incidence rate is reported per 1000 person-years.

†Hypertension is defined as systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg.

 $\pm$ Dyslipidemia is defined as serum low density lipoprotein cholesterol  $\geq$ 140 mg/dL, serum high density lipoprotein cholesterol <40 mg/dL, and/or serum triglycerides  $\geq$ 150 mg/dL.

Table 3. New onset of chronic kidney disease defined by the Asia-Pacific BMI classification in non-diabetic Japanese citizens of Zentsuji City (1998–2023)

|  |                             |                |               |             | Crude                | Model 1                | Model 2                 | Model 3                   |  |  |  |
|--|-----------------------------|----------------|---------------|-------------|----------------------|------------------------|-------------------------|---------------------------|--|--|--|
| Asia-Pacific BMI classification  | PY                          | Failure        | IR‡           | TR (95% CI) | aTR (95% CI)         | aTR (95% CI)           | aTR (95% CI)            |                           |  |  |  |
| Men (n=3098)   |                             |                | •             |             |                      |                        |                         |                           |  |  |  |
| $<18.5 \text{ kg/m}^2$   | Underweight                 | 1145.5         | 40            | 34.9        | 1.08 (1.00–1.16)     | 1.08 (0.99–1.17)       | 1.08 (0.99–1.17)        | 1.08 (1.00–1.17)          |  |  |  |
| $18.5-22.9 \text{ kg/m}^2$ (reference)   | Normal weight               | 9941.5         | 438           | 44.1        | 1.00                 | 1.00                   | 1.00                    | 1.00                      |  |  |  |
| $23.0-24.9 \text{ kg/m}^2$   | Overweight                  | 5877.1         | 272           | 46.3        | 0.97 (0.94–1.01)     | 0.97 (0.94-1.00)       | 0.97 (0.93-1.00)        | 0.97 (0.94–1.01)          |  |  |  |
| $25.0-29.9 \text{ kg/m}^2$   | Obesity class I             | 5532.7 2       |               | 51.9        | 0.94 (0.90-0.97)     | 0.93 (0.90-0.97)       | 0.93 (0.90-0.97)        | 0.94 (0.90-0.98)          |  |  |  |
| $\geq$ 30.0 kg/m <sup>2</sup>  | Obesity class II            | 468.8          | 22            | 46.9        | 0.92 (0.82–1.02)     | 0.92 (0.82–1.02)       | 0.92 (0.82–1.02)        | 0.92 (0.82–1.02)          |  |  |  |
|  |                             |                |               |             | Crude                | Model 1                | Model 2                 | Model 3                   |  |  |  |
| Asia-Pacific BMI classification  |                             | PY             | Failure       | IR‡         | TR (95% CI)          | aTR (95% CI)           | aTR (95% CI)            | aTR (95% CI)              |  |  |  |
| Women (n=4391)   |                             |                |               |             |                      |                        |                         |                           |  |  |  |
| $<18.5 \text{ kg/m}^2$   | Underweight                 | 2804.2         | 106           | 37.8        | 1.02 (0.97-1.06)     | 1.02 (0.98–1.06)       | 1.02 (0.97-1.06)        | 1.01 (0.96–1.05) ad       |  |  |  |
| $18.5-22.9 \text{ kg/m}^2$ (reference)   | Normal weight               | 18306.5 6      |               | 38.1        | 1.00                 | 1.00                   | 1.00                    | ۵ م<br>چ                  |  |  |  |
| $23.0-24.9 \text{ kg/m}^2$   | Overweight                  | 7424.3         | 307           | 41.4        | 0.99 (0.96–1.02)     | 0.99 (0.96–1.02)       | 0.99 (0.96–1.02)        | 1.00 (0.97–1.03) <u>a</u> |  |  |  |
| $25.0-29.9 \text{ kg/m}^2$   | Obesity class I             | 6627.6         | 371           | 56.0        | 0.94 (0.92–0.97)     | 0.95 (0.92-0.97)       | 0.95 (0.92–0.97)        | 0.95 (0.93–0.98)          |  |  |  |
| $\geq$ 30.0 kg/m <sup>2</sup>  | Obesity class II            | 1055.4         | 45            | 42.6        | 0.97 (0.91–1.03)     | 0.97 (0.91-1.03)       | 0.97 (0.91–1.03)        | 0.98 (0.92–1.05)          |  |  |  |
| Abbreviations: aTR, adjusted time  | ratio; BMI, body mass       | index; CI, con | nfidence inte | rval; HbA   | A1c, hemoglobin A1C; | IR, incidence rate; PY | , person-years; TR, tim | e ratio.                  |  |  |  |
| *Hypertension is defined as systolic   | c blood pressure $\geq 130$ | mmHg and/or    | diastolic blo | ood pressu  | ıre ≥80 mmHg.        |                        |                         | <u> </u>                  |  |  |  |
| †Dyslipidemia is defined as serum low-density lipoprotein cholesterol ≥140 mg/dL, serum high-density lipoprotein cholesterol <40 mg/dL, and/or serum triglycerides ≥150 mg/dL. |                             |                |               |             |                      |                        |                         |                           |  |  |  |
| ‡Incidence rate is reported per 1000 person-years.   |                             |                |               |             |                      |                        |                         |                           |  |  |  |
| Multiple imputed variables: hypertension*, dyslipidemia <sup>+</sup> , self-reported alcohol intake, self-reported smoking status, and residential district.                   |                             |                |               |             |                      |                        |                         |                           |  |  |  |
| Model 1: Adjusted for age category (34–59[reference]/60–69/70–100).  |                             |                |               |             |                      |                        |                         |                           |  |  |  |
| Model 2: Adjusted for the variable of Model 1, self-reported alcohol intake (non- or seldom-drinker [reference]/drinker), and self-reported smoking status (non- or ex-smoker  |                             |                |               |             |                      |                        |                         |                           |  |  |  |
| Model 3: Adjusted for all variables of Model 2, hypertension* (no[reference]/yes), dyslipidemia† (no[reference]/yes), HbA1c values, and residential district                   |                             |                |               |             |                      |                        |                         |                           |  |  |  |
| (Lastrerence) ratsukawa/Central  |                             | 1 Ushi wara/ 1 | ogna).        |             |                      |                        |                         | licer                     |  |  |  |
|  |                             |                |               |             |                      |                        |                         | nse                       |  |  |  |